Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. SKAN Group AG's accounts receivables for the quarter that ended in Dec. 2025 was €37.6 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
SKAN Group AG's Days Sales Outstanding for the quarter that ended in Dec. 2025 was 32.18.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. SKAN Group AG's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was €-8.88.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
SKAN Group AG's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), SKAN Group AG's accounts receivable are only considered to be worth 75% of book value:
SKAN Group AG's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
SKAN Group AG Accounts Receivable Related Terms
SKAN Group AG Accounts Receivable Historical Data
* Premium members only.
The historical data trend for SKAN Group AG's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of €37.6 Mil mean?
SKAN Group AG (FRA:7VG) has a Accounts Receivable of €37.6 Mil as of Dec. 2025. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on SKAN Group AG and its competitors.
Is SKAN Group AG's Accounts Receivable too high?
SKAN Group AG's current Accounts Receivable is €37.6 Mil. Overall, SKAN Group AG has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SKAN Group AG's Accounts Receivable compare to ISRG and BDX?
SKAN Group AG's Accounts Receivable of €37.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on SKAN Group AG and its competitors. SKAN Group AG's current Accounts Receivable is €37.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SKAN Group AG stock overvalued right now?
Based on GuruFocus' analysis, SKAN Group AG (FRA:7VG) is currently considered Significantly Undervalued. The stock's GF Value™ is €92.26, compared to a current price of €63.00 — trading 31.7% below its estimated fair value. The current Accounts Receivable is €37.6 Mil. SKAN Group AG's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For SKAN Group AG (FRA:7VG), the current Accounts Receivable is €37.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SKAN Group AG (FRA:7VG) Overvalued in 2026?
Based on GuruFocus' analysis, SKAN Group AG stock appears to be undervalued.
The current stock price of €63.00 is trading 31.7% below its estimated GF Value™ of €92.26.
GuruFocus considers SKAN Group AG to be Significantly Undervalued.
Key valuation signals for FRA:7VG:
Accounts Receivable: €37.6 Mil
GF Value™: €92.26 vs. price of €63.00 (31.7% below fair value)
No single metric tells the full story. See the FRA:7VG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, transfer systems, and others. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
66GF Score
Get the complete analysis for FRA:7VG
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VG has been successfully added to your 
